CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Revenues:
License and milestone fees	$ 6,070	$ 6,234
Royalty revenue		4,166
Non-cash royalty revenue related to the sale of future royalties	5,684
Research and development support	772	776
Clinical materials revenue	2,325	2,027
Total revenues	14,851	13,203
Operating Expenses:
Research and development	35,132	28,018
General and administrative	8,329	7,095
Total operating expenses	43,461	35,113
Loss from operations	(28,610)	(21,910)
Investment income, net	51	8
Non-cash interest expense on liability related to the sale of future royalties	(5,143)
Other expense, net	(38)	(380)
Net loss	$ (33,740)	$ (22,282)
Basic and diluted net loss per common share (in dollars per share)	$ (0.39)	$ (0.26)
Basic and diluted weighted average common shares outstanding (in shares)	86,838	85,872
Total comprehensive loss	$ (33,740)	$ (22,282)